Evidence Report/Technology Assessment Number 97

Pharmacological Treatment of Dementia

File Inventory


Prepared by:

McMaster University Evidence-based Practice Center
McMaster University, Faculty of Health Sciences
Hamilton, Ontario, Canada

Investigators
   Pasqualina (Lina) Santaguida, Ph.D.
   Parminder Raina, Ph.D.
   Lynda Booker, B.A.
   Christopher Patterson, M.D.
   Fulvia Baldassarre, M.Sc.
   David Cowan, M.D.
   Mary Gauld, B.A.
   Mitch Levine, M.D.
   Ayse Unsal, Ph.D.


File Name	Description			Software	Version	File	Size
________________________________________________________________________________________________
001front.doc	Microsoft Word® Document	MS Word®	2002	44KB	3 pages
Contents: Title Page, Preface
________________________________________________________________________________________________
002conts.doc	Microsoft Word® Document	MS Word®	2002	48KB	5 pages
Contents: Table of Contents
________________________________________________________________________________________________
003body.doc	Microsoft Word® Document	MS Word®	2002	6.8MB	149 pages
Contents: Acknowledgements, Structured Abstract;
Chapter 1. Introduction: Diagnosis of Dementia, Analytic Framework: Understanding Therapeutic 
 Aims of Pharmacological Treatment, Figure 1. Pathway for the progression of dementia and the 
 ideal application of drug interventions within this framework, Understanding Efficacy of 
 Pharmacological Interventions in Dementia Trials, Primary Objectives and Scope of Systematic 
 Review;
Chapter 2. Methods: The Research Team, Topic Assessment and Refinement, Table 1. Databases 
 searched for relevant RCTs;
Chapter 3. Results: Eligible Studies, Question 1: Does pharmacotherapy for dementia syndromes 
 improve cognitive symptoms and outcomes?, Figure 2. Flow diagram showing the final number of 
 studies meeting the eligibility criteria, Figure 3. Proportion of studies as a function of 
 year of publication, Table 2. List of Cholinergic neurotransmitter modifying agents and the 
 number of studies vs. placebo for each of these, Figure 4. Weighted Mean Difference (WMD) 
 from the Random Effects Model (Random) for the MMSE comparing carnitine versus placebo, 
 Figure 5. Weighted Mean Difference (WMD) from the Random Effects Model (Random) for the MMSE 
 comparing donepezil and placebo, Figure 6. Weighted Mean Difference (WMD) from the Random 
 Effects Model (Random) for the ADAS-cog comparing donepezil versus placebo, Figure 7. Weighted 
 Mean Difference (WMD) from the Random Effects Model (Random) for the CIBC+ (continuous data) 
 comparing donepezil versus placebo, Figure 8. Relative Risk (RR) from the Random Effects 
 Model (Random) for the CIBIC+ (dichotomous data probability of improving) for a 5 mg dose 
 of donepezil, Figure 9. Relative Risk (RR) from the Fixed Effect Model (fixed) for the CIBIC+ 
 (dichotomous data [improved versus not]) for a 10 mg dose of donepezil, Figure 10. Weighted 
 Mean Difference (WMD) from the Random Effects Model (Random) for the Clinical Dementia Rating 
 (CDR) comparing donepezil versus placebo, Figure 11. Weighted Mean Difference (WMD) from the 
 Random Effects Model (Random) for the ADAS-cog comparing galantamine at 24 mg dose versus 
 placebo, Figure 12. Weighted Mean Difference (WMD) from the Random Effects Model (Random) 
 for the ADAS-cog comparing galantamine at 32 mg dose versus placebo, Figure 13. Relative Risk 
 (RR) from the Random Effects Model (Random) for the CIBIC comparing galantamine at 24 mg dose 
 versus placebo, Figure 14. Relative Risk (RR) from the Fixed Effects Mode Fixed l for CIBIC 
 comparing galantamine at 32 mg dose versus placebo, Figure 15. Weighted Mean Difference (WMD) 
 from the Random Effects Model (Random) for the DAD comparing galantamine at 24 mg dose versus 
 placebo, Figure 16. Weighted Mean Difference (WMD) from the Random Effects Model (Random) for 
 the DAD comparing galantamine at 32 mg dose versus placebo, Figure 17. Weighted Mean Difference 
 (WMD) from the Random Effects Model (Random) for the ADAS-cog comparing rivastigmine versus 
 placebo, Figure 18. Relative Risk (RR) from the Random Effects Model (Random) for the CIBIC+ 
 comparing rivastigmine versus placebo, Table 3. List of Non-cholinergic neurotransmitter/neuropeptide 
 modifying agents and the number of studies vs. placebo for each of these, Table 4. List of Other 
 pharmacological agents and the number of studies vs. placebo for each of these, Figure 19. Weighted 
 Mean Difference (WMD) from the Random Effects Model (Random) for the ADAS-cog comparing cerebrolysin 
 versus placebo, Figure 20. Odd Ratio (OR) from the Random Effects Model (Random) for the CGI 
 comparing cerebrolysin versus placebo, Figure 21. Weighted Mean Difference (WMD) from the Random 
 Effects Model (Random) for the MMSE change score comparing propentofylline versus placebo, 
 Figure 22. Weighted Mean Difference (WMD) from the Random Effects Model (Random) for the DSST change 
 score comparing propentofylline versus placebo, Question 2: Does pharmacotherapy delay cognitive 
 deterioration or delay disease onset of dementia syndromes?, Table 5. Studies that withdrew the 
 treatment agent but maintained at least single blinding, Table 6. Studies that withdrew treatment 
 and did not specify if blinding for washout or extension was maintained, Question 3: Are certain 
 drugs, including alternative medicines (non-pharmaceutical), more effective than others?, 
 Figure 23. Weighted Mean Difference (WMD) from the Random Effects Model (Random) for the ADAS-cog 
 comparing donepezil versus placebo, Figure 24. Weighted Mean Difference (WMD) from the Random 
 Effects Model (Random) for the ADAS-cog comparing galantamine versus placebo, Figure 25. Weighted 
 Mean Difference (WMD) from the Random Effects Model (Random) for the ADAS-cog comparing rivastigmine 
 versus placebo, Figure 26. Weighted Mean Difference (WMD) from the Fixed Effects Model (Fixed) 
 for the ADAS-cog comparing tacrine versus placebo, Figure 27. Relative Risk (RR) from the Random 
 Effects Model (Random) for the CIBIC comparing donepezil versus placebo, Figure 28. Relative Risk 
 (RR) from the Random Effects Model (Random) for the CIBIC comparing galantamine versus placebo, 
 Figure 29. Relative comparison of effect sizes for studies using the CIBIC rivastigmine versus 
 placebo, Figure 30. Relative comparison of effect sizes for studies using the CIBIC comparing tacrine 
 versus placebo, Question 4: Do certain patient populations benefit more from pharmacotherapy than 
 others?, Table 7. Studies with stratified analyses, Question 5: What is the evidence for the treatment 
 of VaD?, Table 8. Studies evaluating vascular dementia patients relative to other dementias, 
 Table 9. Guide to Overall Summary Tables - Outcome Measures Classified by Domain;
Summary Evidence Tables: Summary Table 1. Carnitine, Summary Table 2. Donepezil, Summary Table 3. 
 Galantamine, Summary Table 4. Metrifonate, Summary Table 5. Nicergoline, Summary Table 6. Physostigmine, 
 Summary Table 7. Posatirelin, Summary Table 8. Rivastigmine, Summary Table 9. Tacrine, Summary Table 
 10. Velnacrine, Summary Table 11. Various cholinergic neurotransmitter modifying agents, Summary Table 
 12. Haloperidol, Summary Table 13. Memantine, Summary Table 14. Selegeline, Summary Table 15. Various 
 non-cholinergic neurotransmitter/neuropeptide modifying agents, Summary Table 16. Cerebrolysin, 
 Summary Table 17. Estrogens, Summary Table 18. Ginkgo Biloba, Summary Table 19. Idebenone, Summary Table 
 20. Oxiracetam, Summary Table 21. Pentoxifylline, Summary Table 22. Propentofylline, Summary Table 23. 
 Additional pharmacological agents, Summary Table 24. Drug vs drug studies, Summary Table 25. VaD/MID 
 Studies;
Chapter 4. Discussion: Strength of the Evidence, Question 1: Does pharmacotherapy for dementia syndromes 
 improve cognitive symptoms and outcomes?, Question 2: Does pharmacotherapy delay cognitive deterioration 
 or delay disease onset of dementia syndromes?, Figure 31. Delay of symptomatic treatment effects, 
 Figure 32. Delay in disease progression treatment effects, Question 3: Are certain drugs, including 
 alternative medicines (including non-pharmaceutical) more effective than others?, Question 4: Do certain 
 patient populations benefit more from pharmacotherapy than others?, Question 5: What is the evidence-base 
 for the treatment of vascular dementia?, Determining Clinical Relevance, Limitations of the McMaster 
 AHRQ Review, Future Research Recommendations, References
________________________________________________________________________________________________
004acros.doc	Microsoft Word® Document	MS Word®	2002	314KB	7 pages
Contents: Acronyms and Abbreviations
________________________________________________________________________________________________
005bib.doc	Microsoft Word® Document	MS Word®	2002	617KB	120 pages
Contents: Bibliography
________________________________________________________________________________________________
006apscv.doc	Microsoft Word® Document	MS Word®	2002	29KB	1 page
Contents: Cover Page: Appendixes
________________________________________________________________________________________________
007apacv.doc	Microsoft Word® Document	MS Word®	2002	20KB	1 page
Contents: Cover Page: Appendix A. Search strategies
________________________________________________________________________________________________
008appa.doc	Microsoft Word® Document	MS Word®	2002	61KB	14 pages
Contents: Appendix A. Search strategies
________________________________________________________________________________________________
009apbcv.doc	Microsoft Word® Document	MS Word®	2002	21KB	1 page
Contents: Cover Page: Appendix B. Forms
________________________________________________________________________________________________
010apb1.doc	Microsoft Word® Document	MS Word®	2002	31KB	1 page
Contents: Full Text Screening Form
________________________________________________________________________________________________
011apb2.doc	Microsoft Word® Document	MS Word®	2002	31KB	2 pages
Contents: Gudie to Full Text Screening Form
________________________________________________________________________________________________
012apb3.doc	Microsoft Word® Document	MS Word®	2002	29KB	1 page
Contents: Full Text Screening Form: Secondary Exclusion
________________________________________________________________________________________________
013apb4.doc	Microsoft Word® Document	MS Word®	2002	35KB	1 page
Contents: Quality Score for JADAD Scale and for Modified JADAD Scale
________________________________________________________________________________________________
014apb5.doc	Microsoft Word® Document	MS Word®	2002	42KB	2 pages
Contents: Table A. Key Characteristics
________________________________________________________________________________________________
015apb6.doc	Microsoft Word® Document	MS Word®	2002	35KB	2 pages
Contents: Table B. Evidence Results
________________________________________________________________________________________________
016apb7.doc	Microsoft Word® Document	MS Word®	2002	23KB	1 page
Contents: Overall Summary Table Interpretation
________________________________________________________________________________________________
017apb8.doc	Microsoft Word® Document	MS Word®	2002	39KB	2 pages
Contents: Reporting Safety information in Randomized controlled trials
________________________________________________________________________________________________
018apccv.doc	Microsoft Word® Document	MS Word®	2002	21KB	1 page
Contents: Cover Page: Appendix C. Evidence tables
________________________________________________________________________________________________
019apcgd.doc	Microsoft Word® Document	MS Word®	2002	108KB	3 pages
Contents: Guide to the Results Tables
________________________________________________________________________________________________
020et1.doc	Microsoft Word® Document	MS Word®	2002	48KB	3 pages
Contents: Evidence Table 1. Key characteristics: Carnitine (ALCAR)
________________________________________________________________________________________________
021et2.doc	Microsoft Word® Document	MS Word®	2002	43KB	1 page
Contents: Evidence Table 2. Study results: Carnitine (ALCAR)
________________________________________________________________________________________________
022et3.doc	Microsoft Word® Document	MS Word®	2002	40KB	1 page
Contents: Evidence Table 3. Study results: Carnitine (ALCAR)
________________________________________________________________________________________________
023et4.doc	Microsoft Word® Document	MS Word®	2002	37KB	1 page
Contents: Evidence Table 4. Study results: Carnitine (ALCAR)
________________________________________________________________________________________________
024et5.doc	Microsoft Word® Document	MS Word®	2002	40KB	1 page
Contents: Evidence Table 5. Study results: Carnitine (ALCAR)
________________________________________________________________________________________________
025et6.doc	Microsoft Word® Document	MS Word®	2002	36KB	1 page
Contents: Evidence Table 6. Study results: Carnitine (ALCAR)
________________________________________________________________________________________________
026et7.doc	Microsoft Word® Document	MS Word®	2002	41KB	1 page
Contents: Evidence Table 7. Study results: Carnitine (ALCAR)
________________________________________________________________________________________________
027et8.doc	Microsoft Word® Document	MS Word®	2002	94KB	1 page
Contents: Evidence Table 8. Adverse Events: Carnitine (ALCAR)
________________________________________________________________________________________________
028et9.doc	Microsoft Word® Document	MS Word®	2002	66KB	4 pages
Contents: Evidence Table 9. Key characteristics: Donepezil (DPZ)
________________________________________________________________________________________________
029et10.doc	Microsoft Word® Document	MS Word®	2002	40KB	1 page
Contents: Evidence Table 10. Study results: Donepezil (DPZ)
________________________________________________________________________________________________
030et11.doc	Microsoft Word® Document	MS Word®	2002	43KB	1 page
Contents: Evidence Table 11. Study results: Donepezil (DPZ)
________________________________________________________________________________________________
031et12.doc	Microsoft Word® Document	MS Word®	2002	37KB	1 page
Contents: Evidence Table 12. Study results: Donepezil (DPZ)
________________________________________________________________________________________________
032et13.doc	Microsoft Word® Document	MS Word®	2002	33KB	1 page
Contents: Evidence Table  13. Study results: Donepezil (DPZ)
________________________________________________________________________________________________
033et14.doc	Microsoft Word® Document	MS Word®	2002	35KB	1 page
Contents: Evidence Table 14. Study results: Denepezil
________________________________________________________________________________________________
034et15.doc	Microsoft Word® Document	MS Word®	2002	42KB	1 page
Contents: Evidence Table 15. Study results: Donepezil (DPZ)
________________________________________________________________________________________________
035et16.doc	Microsoft Word® Document	MS Word®	2002	39KB	1 page
Contents: Evidence Table 16. Study results: Donepezil (DPZ)
________________________________________________________________________________________________
036et17.doc	Microsoft Word® Document	MS Word®	2002	38KB	1 page
Contents: Evidence Table 17. Study results: Donepezil (DPZ)
________________________________________________________________________________________________
037et18.doc	Microsoft Word® Document	MS Word®	2002	39KB	1 page
Contents: Evidence Table 18. Study results: Donepezil (DPZ)
________________________________________________________________________________________________
038et19.doc	Microsoft Word® Document	MS Word®	2002	38KB	1 page
Contents: Evidence Table 19. Study results: Donepezil (DPZ), Vitamin E
________________________________________________________________________________________________
039et20.doc	Microsoft Word® Document	MS Word®	2002	37KB	1 page
Contents: Evidence Table 20. Study results: Donepezil (DPZ)
________________________________________________________________________________________________
040et21.doc	Microsoft Word® Document	MS Word®	2002	100KB	1 page
Contents: Evidence Table 21. Adverse Events: Donepezil (DPZ)
________________________________________________________________________________________________
041et22.doc	Microsoft Word® Document	MS Word®	2002	45KB	2 pages
Contents: Evidence Table 22. Key characteristics: Galantamine
________________________________________________________________________________________________
042et23.doc	Microsoft Word® Document	MS Word®	2002	38KB	1 page
Contents: Evidence Table 23. Study results: Galantamine
________________________________________________________________________________________________
043et24.doc	Microsoft Word® Document	MS Word®	2002	34KB	1 page
Contents: Evidence Table 24. Study results: Galantamine
________________________________________________________________________________________________
044et25.doc	Microsoft Word® Document	MS Word®	2002	34KB	1 page
Contents: Evidence Table 25. Study results: Galantamine
________________________________________________________________________________________________
045et26.doc	Microsoft Word® Document	MS Word®	2002	36KB	1 page
Contents: Evidence Table 26. Study results: Galantamine
________________________________________________________________________________________________
046et27.doc	Microsoft Word® Document	MS Word®	2002	35KB	1 page
Contents: Evidence Table 27. Study results: Galantamine
________________________________________________________________________________________________
047et28.doc	Microsoft Word® Document	MS Word®	2002	35KB	1 page
Contents: Evidence Table 28. Study results: Galantamine
________________________________________________________________________________________________
048et29.doc	Microsoft Word® Document	MS Word®	2002	94KB	1 page
Contents: Evidence Table 29. Adverse Events: Galantamine
________________________________________________________________________________________________
049et30.doc	Microsoft Word® Document	MS Word®	2002	62KB	5 pages
Contents: Evidence Table 30. Key characteristics. Metrifonate
________________________________________________________________________________________________
050et31.doc	Microsoft Word® Document	MS Word®	2002	38KB	1 page
Contents: Evidence Table 31. Study results: Metrifonate
________________________________________________________________________________________________
051et32.doc	Microsoft Word® Document	MS Word®	2002	37KB	1 page
Contents: Evidence Table 32. Study results: Metrifonate
________________________________________________________________________________________________
052et33.doc	Microsoft Word® Document	MS Word®	2002	34KB	1 page
Contents: Evidence Table 33. Study results: Metrifonate
________________________________________________________________________________________________
053et34.doc	Microsoft Word® Document	MS Word®	2002	38KB	1 page
Contents: Evidence Table 34. Study results: Metrifonate
________________________________________________________________________________________________
054et35.doc	Microsoft Word® Document	MS Word®	2002	38KB	1 page
Contents: Evidence Table 35. Study results: Metrifonate
________________________________________________________________________________________________
055et36.doc	Microsoft Word® Document	MS Word®	2002	34KB	1 page
Contents: Evidence Table 36. Study results: Metrifonate
________________________________________________________________________________________________
056et37.doc	Microsoft Word® Document	MS Word®	2002	37KB	1 page
Contents: Evidence Table 37. Study results: Metrifonate
________________________________________________________________________________________________
057et38.doc	Microsoft Word® Document	MS Word®	2002	36KB	1 page
Contents: Evidence Table 38. Study results: Metrifonate
________________________________________________________________________________________________
058et39.doc	Microsoft Word® Document	MS Word®	2002	36KB	1 page
Contents: Evidence Table 39. Study results: Metrifonate
________________________________________________________________________________________________
059et40.doc	Microsoft Word® Document	MS Word®	2002	89KB	1 page
Contents: Evidence Table 40. Adverse Events: Metrifonate
________________________________________________________________________________________________
060et41.doc	Microsoft Word® Document	MS Word®	2002	42KB	2 pages
Contents: Evidence Table 41. Key characteristics: Nicergoline
________________________________________________________________________________________________
061et42.doc	Microsoft Word® Document	MS Word®	2002	39KB	1 page
Contents: Evidence Table 42. Study results: Nicergoline
________________________________________________________________________________________________
062et43.doc	Microsoft Word® Document	MS Word®	2002	34KB	1 page
Contents: Evidence Table 43. Study results: Nicergoline
________________________________________________________________________________________________
063et44.doc	Microsoft Word® Document	MS Word®	2002	40KB	1 page
Contents: Evidence Table 44. Study results: Nicergoline
________________________________________________________________________________________________
064et45.doc	Microsoft Word® Document	MS Word®	2002	38KB	1 page
Contents: Evidence Table 45. Study results: Nicergoline
________________________________________________________________________________________________
065et46.doc	Microsoft Word® Document	MS Word®	2002	33KB	1 page
Contents: Evidence Table 46. Study results: Nicergoline - Antagonic Stress
________________________________________________________________________________________________
066et47.doc	Microsoft Word® Document	MS Word®	2002	79KB	1 page
Contents: Evidence Table 47. Adverse Events: Nicergoline
________________________________________________________________________________________________
067et48.doc	Microsoft Word® Document	MS Word®	2002	39KB	2 pages
Contents: Evidence Table 48. Key characteristics: Physostigmine
________________________________________________________________________________________________
068et49.doc	Microsoft Word® Document	MS Word®	2002	37KB	1 page
Contents: Evidence Table 49. Study results: Physostigmine
________________________________________________________________________________________________
069et50.doc	Microsoft Word® Document	MS Word®	2002	33KB	1 page
Contents: Evidence Table 50. Study results: Physostigmine
________________________________________________________________________________________________
070et51.doc	Microsoft Word® Document	MS Word®	2002	35KB	1 page
Contents: Evidence Table 51. Study results: Physostigmine
________________________________________________________________________________________________
071et52.doc	Microsoft Word® Document	MS Word®	2002	33KB	1 page
Contents: Evidence Table 52. Study results: Physostigmine
________________________________________________________________________________________________
072et53.doc	Microsoft Word® Document	MS Word®	2002	67KB	1 page
Contents: Evidence Table 53. Adverse Events: Physostigmine
________________________________________________________________________________________________
073et54.doc	Microsoft Word® Document	MS Word®	2002	35KB	1 page
Contents: Evidence Table 54. Key characteristics: Posatirelin
________________________________________________________________________________________________
074et55.doc	Microsoft Word® Document	MS Word®	2002	39KB	1 page
Contents: Evidence Table 55. Study results: Posatirelin
________________________________________________________________________________________________
075et56.doc	Microsoft Word® Document	MS Word®	2002	36KB	1 page
Contents: Evidence Table 56. Study results: Posatirelin
________________________________________________________________________________________________
076et57.doc	Microsoft Word® Document	MS Word®	2002	38KB	1 page
Contents: Evidence Table 57. Study results: Posatirelin
________________________________________________________________________________________________
077et58.doc	Microsoft Word® Document	MS Word®	2002	45KB	1 page
Contents: Evidence Table 58. Study results: Citicoline - Posatirelin
________________________________________________________________________________________________
078et59.doc	Microsoft Word® Document	MS Word®	2002	66KB	1 page
Contents: Evidence Table 59. Adverse Events: Posatirelin
________________________________________________________________________________________________
079et60.doc	Microsoft Word® Document	MS Word®	2002	49KB	3 pages
Contents: Evidence Table 60. Key characteristics: Rivastigmine
________________________________________________________________________________________________
080et61.doc	Microsoft Word® Document	MS Word®	2002	46KB	2 pages
Contents: Evidence Table 61. Study results: Rivastigmine
________________________________________________________________________________________________
081et62.doc	Microsoft Word® Document	MS Word®	2002	39KB	1 page
Contents: Evidence Table 62. Study results: Rivastigmine
________________________________________________________________________________________________
082et63.doc	Microsoft Word® Document	MS Word®	2002	39KB	1 page
Contents: Evidence Table 63. Study results: Rivastigmine
________________________________________________________________________________________________
083et64.doc	Microsoft Word® Document	MS Word®	2002	39KB	1 page
Contents: Evidence Table 64. Study results: Rivastigmine
________________________________________________________________________________________________
084et65.doc	Microsoft Word® Document	MS Word®	2002	35KB	1 page
Contents: Evidence Table 65. Study results: Rivastigmine
________________________________________________________________________________________________
085et66.doc	Microsoft Word® Document	MS Word®	2002	40KB	1 page
Contents: Evidence Table 66. Study results: Rivastigmine
________________________________________________________________________________________________
086et67.doc	Microsoft Word® Document	MS Word®	2002	94KB	1 page
Contents: Evidence Table 67. Adverse Events: Rivastigmine
________________________________________________________________________________________________
087et68.doc	Microsoft Word® Document	MS Word®	2002	59KB	4 pages
Contents: Evidence Table 68. Key characteristics: Tacrine
________________________________________________________________________________________________
088et69.doc	Microsoft Word® Document	MS Word®	2002	34KB	1 page
Contents: Evidence Table 69. Study results: Tacrine
________________________________________________________________________________________________
089et70.doc	Microsoft Word® Document	MS Word®	2002	39KB	1 page
Contents: Evidence Table 70. Study results: Idebenone-Tacrine
________________________________________________________________________________________________
090et71.doc	Microsoft Word® Document	MS Word®	2002	40KB	1 page
Contents: Evidence Table 71. Study results: Tacrine
________________________________________________________________________________________________
091et72.doc	Microsoft Word® Document	MS Word®	2002	40KB	1 page
Contents: Evidence Table 72. Study results: Tacrine & Lethicin
________________________________________________________________________________________________
092et73.doc	Microsoft Word® Document	MS Word®	2002	34KB	1 page
Contents: Evidence Table 73. Study results: Tacrine
________________________________________________________________________________________________
093et74.doc	Microsoft Word® Document	MS Word®	2002	34KB	1 page
Contents: Evidence Table 74. Study results: Tetrahydroaminoacridine & Lethicin
________________________________________________________________________________________________
094et75.doc	Microsoft Word® Document	MS Word®	2002	36KB	1 page
Contents: Evidence Table 75. Study results: Tacrine
________________________________________________________________________________________________
095et76.doc	Microsoft Word® Document	MS Word®	2002	36KB	1 page
Contents: Evidence Table 76. Study results: Tacrine
________________________________________________________________________________________________
096et77.doc	Microsoft Word® Document	MS Word®	2002	86KB	1 page
Contents: Evidence Table 77. Adverse Events: Tacrine
________________________________________________________________________________________________
097et78.doc	Microsoft Word® Document	MS Word®	2002	31KB	1 page
Contents: Evidence Table 78. Key characteristics: Velnacrine
________________________________________________________________________________________________
098et79.doc	Microsoft Word® Document	MS Word®	2002	39KB	1 page
Contents: Evidence Table 79. Study results: Velnacrine
________________________________________________________________________________________________
099et80.doc	Microsoft Word® Document	MS Word®	2002	36KB	1 page
Contents: Evidence Table 80. Study results: HP 128 (Velnarcrine)
________________________________________________________________________________________________
100et81.doc	Microsoft Word® Document	MS Word®	2002	33KB	1 page
Contents: Evidence Table 81. Study results: Velnacrine
________________________________________________________________________________________________
101et82.doc	Microsoft Word® Document	MS Word®	2002	62KB	1 page
Contents: Evidence Table 82. Adverse Events: Velnacrine
________________________________________________________________________________________________
102et83.doc	Microsoft Word® Document	MS Word®	2002	52KB	2 pages
Contents: Evidence Table 83. Key Characteristics: Various cholinergic neurotransmitter 
modifying agents
________________________________________________________________________________________________
103et84.doc	Microsoft Word® Document	MS Word®	2002	36KB	1 page
Contents: Evidence Table 84. Study results: Eptastigmine
________________________________________________________________________________________________
104et85.doc	Microsoft Word® Document	MS Word®	2002	35KB	1 page
Contents: Evidence Table 85. Study results: Eptastigmine
________________________________________________________________________________________________
105et86.doc	Microsoft Word® Document	MS Word®	2002	40KB	1 page
Contents: Evidence Table 86. Study results: Haboyin (Huperzine-A)
________________________________________________________________________________________________
106et87.doc	Microsoft Word® Document	MS Word®	2002	39KB	1 page
Contents: Evidence Table 87. Study results: Linopirdine
________________________________________________________________________________________________
107et88.doc	Microsoft Word® Document	MS Word®	2002	33KB	1 page
Contents: Evidence Table 88. Study results: Linopirdine
________________________________________________________________________________________________
108et89.doc	Microsoft Word® Document	MS Word®	2002	38KB	1 page
Contents: Evidence Table 89. Study results: Sabeluzole
________________________________________________________________________________________________
109et90.doc	Microsoft Word® Document	MS Word®	2002	34KB	1 page
Contents: Evidence Table 90. Study results: Antagonic Stress - Meclofenoxate
________________________________________________________________________________________________
110et91.doc	Microsoft Word® Document	MS Word®	2002	33KB	1 page
Contents: Evidence Table 91. Study results: Nicergoline - Antagonic Stress
________________________________________________________________________________________________
111et92.doc	Microsoft Word® Document	MS Word®	2002	38KB	1 page
Contents: Evidence Table 92. Study results: Huperzine A
________________________________________________________________________________________________
112et93.doc	Microsoft Word® Document	MS Word®	2002	94KB	1 page
Contents: Evidence Table 93. Adverse Events: Neurotransmitters - Various Cholinergic 
neurotransmitter modifying agents
________________________________________________________________________________________________
113et94.doc	Microsoft Word® Document	MS Word®	2002	53KB	3 pages
Contents: Evidence Table 94. Key characteristics: Haloperidol
________________________________________________________________________________________________
114et95.doc	Microsoft Word® Document	MS Word®	2002	38KB	1 page
Contents: Evidence Table 95. Study results: Haloperidol - Tiapride
________________________________________________________________________________________________
115et96.doc	Microsoft Word® Document	MS Word®	2002	36KB	1 page
Contents: Evidence Table 96. Study results: Haloperidol - Fluoxetine
________________________________________________________________________________________________
116et97.doc	Microsoft Word® Document	MS Word®	2002	41KB	1 page
Contents: Evidence Table 97. Study results: Risperidone - Haloperidol
________________________________________________________________________________________________
117et98.doc	Microsoft Word® Document	MS Word®	2002	38KB	1 page
Contents: Evidence Table 98. Study results: Loxapine - Haloperidol
________________________________________________________________________________________________
118et99.doc	Microsoft Word® Document	MS Word®	2002	45KB	2 pages
Contents: Evidence Table 99. Study results: Haloperidol - Trazodone
________________________________________________________________________________________________
119et100.doc	Microsoft Word® Document	MS Word®	2002	36KB	1 page
Contents: Evidence Table 100. Study results: Loxapine - Haloperidol
________________________________________________________________________________________________
120et101.doc	Microsoft Word® Document	MS Word®	2002	40KB	1 page
Contents: Evidence Table 101. Study results: Haloperidol - Oxazepam - Diphenhydramine
________________________________________________________________________________________________
121et102.doc	Microsoft Word® Document	MS Word®	2002	36KB	1 page
Contents: Evidence Table 102. Study results: Haloperidol - Risperidone
________________________________________________________________________________________________
122et103.doc	Microsoft Word® Document	MS Word®	2002	125KB	2 pages
Contents: Evidence Table 103. Adverse Events: Haloperidol
________________________________________________________________________________________________
123et104.doc	Microsoft Word® Document	MS Word®	2002	34KB	1 page
Contents: Evidence Table 104. Key characteristics: Memantine
________________________________________________________________________________________________
124et105.doc	Microsoft Word® Document	MS Word®	2002	36KB	1 page
Contents: Evidence Table 105. Study results: Memantine
________________________________________________________________________________________________
125et106.doc	Microsoft Word® Document	MS Word®	2002	37KB	1 page
Contents: Evidence Table 106. Study results: Memantine
________________________________________________________________________________________________
126et107.doc	Microsoft Word® Document	MS Word®	2002	35KB	1 page
Contents: Evidence Table 107. Study results: Memantine
________________________________________________________________________________________________
127et108.doc	Microsoft Word® Document	MS Word®	2002	63KB	1 page
Contents: Evidence Table 108. Adverse Events: Memantine
________________________________________________________________________________________________
128et109.doc	Microsoft Word® Document	MS Word®	2002	45KB	2 pages
Contents: Evidence Table 109. Key characteristics: Selegiline
________________________________________________________________________________________________
129et110.doc	Microsoft Word® Document	MS Word®	2002	41KB	1 page
Contents: Evidence Table 110. Study results: Selegiline
________________________________________________________________________________________________
130et111.doc	Microsoft Word® Document	MS Word®	2002	40KB	1 page
Contents: Evidence Table 111. Study results: Selegeline
________________________________________________________________________________________________
131et112.doc	Microsoft Word® Document	MS Word®	2002	47KB	2 pages
Contents: Evidence Table 112. Study results: Selegiline
________________________________________________________________________________________________
132et113.doc	Microsoft Word® Document	MS Word®	2002	38KB	1 page
Contents: Evidence Table 113. Study results: Selegiline
________________________________________________________________________________________________
133et114.doc	Microsoft Word® Document	MS Word®	2002	46KB	2 pages
Contents: Evidence Table 114. Study results: Selegeline
________________________________________________________________________________________________
134et115.doc	Microsoft Word® Document	MS Word®	2002	36KB	1 page
Contents: Evidence Table 115. Study results: Selegiline - Vitamin E
________________________________________________________________________________________________
135et116.doc	Microsoft Word® Document	MS Word®	2002	93KB	1 page
Contents: Evidence Table 116. Adverse Events: Selegiline
________________________________________________________________________________________________
136et117.doc	Microsoft Word® Document	MS Word®	2002	184KB	13 pages
Contents: Evidence Table 117. Key Characteristics. Various non-cholinergic neurotransmitter/
neuropeptide modifying agents
________________________________________________________________________________________________
137et118.doc	Microsoft Word® Document	MS Word®	2002	35KB	1 page
Contents: Evidence Table 118. Study results: Alaproclate
________________________________________________________________________________________________
138et119.doc	Microsoft Word® Document	MS Word®	2002	41KB	2 pages
Contents: Evidence Table 119. Study results: Anapsos
________________________________________________________________________________________________
139et120.doc	Microsoft Word® Document	MS Word®	2002	34KB	1 page
Contents: Evidence Table 120. Study results: BMY-21,502
________________________________________________________________________________________________
140et121.doc	Microsoft Word® Document	MS Word®	2002	36KB	1 page
Contents: Evidence Table 121. Study results: Carbamazepine
________________________________________________________________________________________________
141et122.doc	Microsoft Word® Document	MS Word®	2002	35KB	1 page
Contents: Evidence Table 122. Study results: Carbamazepine
________________________________________________________________________________________________
142et123.doc	Microsoft Word® Document	MS Word®	2002	39KB	1 page
Contents: Evidence Table 123 Study results: Citalopram
________________________________________________________________________________________________
143et124.doc	Microsoft Word® Document	MS Word®	2002	34KB	1 page
Contents: Evidence Table 124. Study results: Citalopram
________________________________________________________________________________________________
144et125.doc	Microsoft Word® Document	MS Word®	2002	38KB	1 page
Contents: Evidence Table 125. Study results: Divalproex
________________________________________________________________________________________________
145et125.doc	Microsoft Word® Document	MS Word®	2002	38KB	1 page
Contents: Evidence Table 125. Study results: Divalproex
________________________________________________________________________________________________
146et126.doc	Microsoft Word® Document	MS Word®	2002	37KB	1 page
Contents: Evidence Table 126. Study results: Divalproex
________________________________________________________________________________________________
147et127.doc	Microsoft Word® Document	MS Word®	2002	44KB	2 pages
Contents: Evidence Table 127. Study results: Fluvoxamine
________________________________________________________________________________________________
148et127.doc	Microsoft Word® Document	MS Word®	2002	40KB	1 page
Contents: Evidence Table 127. Study results: Fluvoxamine
________________________________________________________________________________________________
149et128.doc	Microsoft Word® Document	MS Word®	2002	37KB	1 page
Contents: Evidence Table 128. Study results: Imipramine
________________________________________________________________________________________________
150et129.doc	Microsoft Word® Document	MS Word®	2002	41KB	1 page
Contents: Evidence Table 129. Study results: Lisuride
________________________________________________________________________________________________
151et130.doc	Microsoft Word® Document	MS Word®	2002	36KB	1 page
Contents: Evidence Table 130. Study results: Lu25-109
________________________________________________________________________________________________
152et131.doc	Microsoft Word® Document	MS Word®	2002	35KB	1 page
Contents: Evidence Table 131. Study results: Maprotiline
________________________________________________________________________________________________
153et132.doc	Microsoft Word® Document	MS Word®	2002	42KB	1 page
Contents: Evidence Table 132. Study results: Minaprine
________________________________________________________________________________________________
154et133.doc	Microsoft Word® Document	MS Word®	2002	33KB	1 page
Contents: Evidence Table 133. Study results: Moclobemide
________________________________________________________________________________________________
155et134.doc	Microsoft Word® Document	MS Word®	2002	37KB	1 page
Contents: Evidence Table 134. Study results: Naftidrofuryl
________________________________________________________________________________________________
156et135.doc	Microsoft Word® Document	MS Word®	2002	38KB	1 page
Contents: Evidence Table 135. Study results: Olanzapine
________________________________________________________________________________________________
157et136.doc	Microsoft Word® Document	MS Word®	2002	43KB	1 page
Contents: Evidence Table 136. Study results: Phosphatidylserine (PS)
________________________________________________________________________________________________
158et137.doc	Microsoft Word® Document	MS Word®	2002	38KB	1 page
Contents: Evidence Table 137. Study results: Phosphatidylserine
________________________________________________________________________________________________
159et138.doc	Microsoft Word® Document	MS Word®	2002	38KB	1 page
Contents: Evidence Table 138. Study results: Sertraline
________________________________________________________________________________________________
160et139.doc	Microsoft Word® Document	MS Word®	2002	38KB	1 page
Contents: Evidence Table 139. Study results: Sertraline
________________________________________________________________________________________________
161et140.doc	Microsoft Word® Document	MS Word®	2002	38KB	1 page
Contents: Evidence Table 140. Study results: Fluoxetine
________________________________________________________________________________________________
162et141.doc	Microsoft Word® Document	MS Word®	2002	36KB	1 page
Contents: Evidence Table 142. Study results: Risperidone
________________________________________________________________________________________________
163et142.doc	Microsoft Word® Document	MS Word®	2002	38KB	1 page
Contents: Evidence Table 142. Study results: Risperidone
________________________________________________________________________________________________
164et143.doc	Microsoft Word® Document	MS Word®	2002	43KB	2 pages
Contents: Evidence Table 143. Study results: Haloperidol - Trazodone
________________________________________________________________________________________________
165et144.doc	Microsoft Word® Document	MS Word®	2002	39KB	1 page
Contents: Evidence Table 144. Study results: Risperidone - Haloperidol
________________________________________________________________________________________________
166et145.doc	Microsoft Word® Document	MS Word®	2002	38KB	1 page
Contents: Evidence Table 145. Study results: Haloperidol - Tiapride
________________________________________________________________________________________________
167et146.doc	Microsoft Word® Document	MS Word®	2002	40KB	1 page
Contents: Evidence Table 146. Study results: Olanzapine - Lorazepam
________________________________________________________________________________________________
168et147.doc	Microsoft Word® Document	MS Word®	2002	37KB	1 page
Contents: Evidence Table 147. Study results: Thoridazine - Loxapine
________________________________________________________________________________________________
169et148.doc	Microsoft Word® Document	MS Word®	2002	34KB	1 page
Contents: Evidence Table 148. Study results: Citalopram
________________________________________________________________________________________________
170et149.doc	Microsoft Word® Document	MS Word®	2002	38KB	1 page
Contents: Evidence Table 149. Study results: Xanomeline Tartrate (XT)
________________________________________________________________________________________________
171et150.doc	Microsoft Word® Document	MS Word®	2002	34KB	1 page
Contents: Evidence Table 150. Study results: Haloperidol - Risperidone
________________________________________________________________________________________________
172et151.doc	Microsoft Word® Document	MS Word®	2002	34KB	1 page
Contents: Evidence Table 151. Study results: Fluoxetine
________________________________________________________________________________________________
173et152.doc	Microsoft Word® Document	MS Word®	2002	34KB	1 page
Contents: Evidence Table 152. Study results: Lorazepam, Alprazolam
________________________________________________________________________________________________
174et153.doc	Microsoft Word® Document	MS Word®	2002	33KB	1 page
Contents: Evidence Table 153. Study results: Citalopram
________________________________________________________________________________________________
175et154.doc	Microsoft Word® Document	MS Word®	2002	39KB	1 page
Contents: Evidence Table 154. Study results: Haloperidol - Oxazepam - Diphenhydramine
________________________________________________________________________________________________
176et155.doc	Microsoft Word® Document	MS Word®	2002	34KB	1 page
Contents: Evidence Table 155. Study results: Loxapine - Haloperidol
________________________________________________________________________________________________
177et156.doc	Microsoft Word® Document	MS Word®	2002	36KB	1 page
Contents: Evidence Table 156. Study results: 5'-MTHF - Trazodone
________________________________________________________________________________________________
178et157.doc	Microsoft Word® Document	MS Word®	2002	39KB	1 page
Contents: Evidence Table 157. Study results: Tiapride - Melperone
________________________________________________________________________________________________
179et158.doc	Microsoft Word® Document	MS Word®	2002	37KB	1 page
Contents: Evidence Table 158. Study results: Imipramine - Paroxetine
________________________________________________________________________________________________
180et159.doc	Microsoft Word® Document	MS Word®	2002	37KB	1 page
Contents: Evidence Table 159. Study results: Loxapine - Haloperidol
________________________________________________________________________________________________
181et160.doc	Microsoft Word® Document	MS Word®	2002	437KB	6 pages
Contents: Evidence Table 160. Adverse events. Various cholinergic neurotransmitter 
modifying agents
________________________________________________________________________________________________
182et161.doc	Microsoft Word® Document	MS Word®	2002	44KB	2 pages
Contents: Evidence Table 161. Key characteristics: Cerebrolysin (CERE)
________________________________________________________________________________________________
183et162.doc	Microsoft Word® Document	MS Word®	2002	37KB	1 page
Contents: Evidence Table 162. Study results: Cerebrolysin (CERE)
________________________________________________________________________________________________
184et163.doc	Microsoft Word® Document	MS Word®	2002	36KB	1 page
Contents: Evidence Table 163. Study results: Cerebrolysin (CERE)
________________________________________________________________________________________________
185et164.doc	Microsoft Word® Document	MS Word®	2002	34KB	1 page
Contents: Evidence Table 164. Study results: Cerebrolysin (CERE)
________________________________________________________________________________________________
186et165.doc	Microsoft Word® Document	MS Word®	2002	36KB	1 page
Contents: Evidence Table 165. Study results: Cerebrolysin (CERE)
________________________________________________________________________________________________
187et166.doc	Microsoft Word® Document	MS Word®	2002	42KB	1 page
Contents: Evidence Table 166. Study results: Cerebrolysin (CERE)
________________________________________________________________________________________________
188et167.doc	Microsoft Word® Document	MS Word®	2002	43KB	1 page
Contents: Evidence Table 167. Study results: Cerebrolysin (CERE)
________________________________________________________________________________________________
189et168.doc	Microsoft Word® Document	MS Word®	2002	93KB	1 page
Contents: Evidence Table 168. Adverse Events: Cerebrolysin (CERE)
________________________________________________________________________________________________
190et169.doc	Microsoft Word® Document	MS Word®	2002	45KB	3 pages
Contents: Evidence Table 169. Key characteristics: Estrogens
________________________________________________________________________________________________
191et170.doc	Microsoft Word® Document	MS Word®	2002	35KB	1 page
Contents: Evidence Table 170. Study results: Estradiol
________________________________________________________________________________________________
192et171.doc	Microsoft Word® Document	MS Word®	2002	37KB	1 page
Contents: Evidence Table 171. Study results: Estrogen
________________________________________________________________________________________________
193et172.doc	Microsoft Word® Document	MS Word®	2002	36KB	1 page
Contents: Evidence Table 172. Study results: Estrogen
________________________________________________________________________________________________
194et173.doc	Microsoft Word® Document	MS Word®	2002	52KB	3 pages
Contents: Evidence Table 173. Study results: Estrogen
________________________________________________________________________________________________
195et174.doc	Microsoft Word® Document	MS Word®	2002	36KB	1 page
Contents: Evidence Table 174. Study results: Estrogen
________________________________________________________________________________________________
196et175.doc	Microsoft Word® Document	MS Word®	2002	78KB	1 page
Contents: Evidence Table 175. Adverse Events: Estrogens
________________________________________________________________________________________________
197et176.doc	Microsoft Word® Document	MS Word®	2002	33KB	1 page
Contents: Evidence Table 176. Key characteristics: Gingko Biloba
________________________________________________________________________________________________
198et177.doc	Microsoft Word® Document	MS Word®	2002	38KB	1 page
Contents: Evidence Table 177. Study results: Ginkgo Biloba (EGb761)
________________________________________________________________________________________________
199et178.doc	Microsoft Word® Document	MS Word®	2002	39KB	1 page
Contents: Evidence Table 178. Study results: Ginkgo Biloba (EGb761)
________________________________________________________________________________________________
200et179.doc	Microsoft Word® Document	MS Word®	2002	34KB	1 page
Contents: Evidence Table 179. Study results: Ginkgo Biloba (EGb761, Tebonin forte)
________________________________________________________________________________________________
201et180.doc	Microsoft Word® Document	MS Word®	2002	63KB	1 page
Contents: Evidence Table 180. Adverse Events: Gingko Biloba
________________________________________________________________________________________________
202et181.doc	Microsoft Word® Document	MS Word®	2002	42KB	2 pages
Contents: Evidence Table 181. Key characteristics: Idebenone
________________________________________________________________________________________________
203et182.doc	Microsoft Word® Document	MS Word®	2002	37KB	1 page
Contents: Evidence Table 182. Study results: Idebenone
________________________________________________________________________________________________
204et183.doc	Microsoft Word® Document	MS Word®	2002	36KB	1 page
Contents: Evidence Table 183. Study results: Idebenone
________________________________________________________________________________________________
205et184.doc	Microsoft Word® Document	MS Word®	2002	39KB	1 page
Contents: Evidence Table 184. Study results: Idebenone-Tacrine
________________________________________________________________________________________________
206et185.doc	Microsoft Word® Document	MS Word®	2002	38KB	1 page
Contents: Evidence Table 185. Study results: Idebenone
________________________________________________________________________________________________
207et186.doc	Microsoft Word® Document	MS Word®	2002	39KB	1 page
Contents: Evidence Table 186. Study results: Idebenone
________________________________________________________________________________________________
208et187.doc	Microsoft Word® Document	MS Word®	2002	81KB	1 page
Contents: Evidence Table 187. Adverse Events: Idebenone
________________________________________________________________________________________________
209et188.doc	Microsoft Word® Document	MS Word®	2002	42KB	2 pages
Contents: Evidence Table 188. Key characteristics: Oxiracetam
________________________________________________________________________________________________
210et189.doc	Microsoft Word® Document	MS Word®	2002	41KB	1 page
Contents: Evidence Table 189. Study results: Oxiracetem
________________________________________________________________________________________________
211et190.doc	Microsoft Word® Document	MS Word®	2002	35KB	1 page
Contents: Evidence Table 190. Study results: Oxiracetem
________________________________________________________________________________________________
212et191.doc	Microsoft Word® Document	MS Word®	2002	34KB	1 page
Contents: Evidence Table 191. Study results: Oxiracetem
________________________________________________________________________________________________
213et192.doc	Microsoft Word® Document	MS Word®	2002	38KB	1 page
Contents: Evidence Table 192. Study results: Oxiracetem
________________________________________________________________________________________________
214et193.doc	Microsoft Word® Document	MS Word®	2002	39KB	1 page
Contents: Evidence Table 193. Study results: Oxiracetem
________________________________________________________________________________________________
215et194.doc	Microsoft Word® Document	MS Word®	2002	77KB	1 page
Contents: Evidence Table 194. Adverse Events: Oxiracetam
________________________________________________________________________________________________
216et195.doc	Microsoft Word® Document	MS Word®	2002	35KB	1 page
Contents: Evidence Table 195. Key characteristics. Pentoxifylline
________________________________________________________________________________________________
217et196.doc	Microsoft Word® Document	MS Word®	2002	35KB	1 page
Contents: Evidence Table 196. Study results: Pentoxifylline
________________________________________________________________________________________________
218et197.doc	Microsoft Word® Document	MS Word®	2002	41KB	1 page
Contents: Evidence Table 197. Study results: Pentoxifylline
________________________________________________________________________________________________
219et198.doc	Microsoft Word® Document	MS Word®	2002	37KB	1 page
Contents: Evidence Table 198. Study results: Oxpentifylline
________________________________________________________________________________________________
220et199.doc	Microsoft Word® Document	MS Word®	2002	34KB	1 page
Contents: Evidence Table 199. Study results: Sulodexide - Pentoxifylline
________________________________________________________________________________________________
221et200.doc	Microsoft Word® Document	MS Word®	2002	69KB	1 page
Contents: Evidence Table 200. Adverse Events. Pentoxifylline
________________________________________________________________________________________________
222et201.doc	Microsoft Word® Document	MS Word®	2002	40KB	2 pages
Contents: Evidence Table 201. Key characteristics: Propentofylline
________________________________________________________________________________________________
223et202.doc	Microsoft Word® Document	MS Word®	2002	40KB	1 page
Contents: Evidence Table 202. Study results: Propentofylline
________________________________________________________________________________________________
224et203.doc	Microsoft Word® Document	MS Word®	2002	33KB	1 page
Contents: Evidence Table 203. Study results: Propentofylline
________________________________________________________________________________________________
225et204.doc	Microsoft Word® Document	MS Word®	2002	37KB	1 page
Contents: Evidence Table 204. Study results: Propentofylline
________________________________________________________________________________________________
226et205.doc	Microsoft Word® Document	MS Word®	2002	40KB	1 page
Contents: Evidence Table 205. Study results: Propentofylline
________________________________________________________________________________________________
227et206.doc	Microsoft Word® Document	MS Word®	2002	67KB	1 page
Contents: Evidence Table 206. Adverse Events: Propentofylline
________________________________________________________________________________________________
228et207.doc	Microsoft Word® Document	MS Word®	2002	173KB	12 pages
Contents: Evidence Table 207. Key characteristics: Other agents
________________________________________________________________________________________________
229et208.doc	Microsoft Word® Document	MS Word®	2002	42KB	1 page
Contents: Evidence Table 208. Study results: Aniracetam
________________________________________________________________________________________________
230et209.doc	Microsoft Word® Document	MS Word®	2002	37KB	1 page
Contents: Evidence Table 209. Study results: Ateroid
________________________________________________________________________________________________
231et210.doc	Microsoft Word® Document	MS Word®	2002	35KB	1 page
Contents: Evidence Table 210. Study results: BMY 21,502
________________________________________________________________________________________________
232et211.doc	Microsoft Word® Document	MS Word®	2002	40KB	1 page
Contents: Evidence Table 211. Study results: Buflomedil
________________________________________________________________________________________________
233et212.doc	Microsoft Word® Document	MS Word®	2002	37KB	1 page
Contents: Evidence Table 212. Study results: CBM 36-733 (Ergokryptine)
________________________________________________________________________________________________
234et213.doc	Microsoft Word® Document	MS Word®	2002	41KB	1 page
Contents: Evidence Table 213. Study results: Choto-san
________________________________________________________________________________________________
235et214.doc	Microsoft Word® Document	MS Word®	2002	35KB	1 page
Contents: Evidence Table 214. Study results: Choto-san
________________________________________________________________________________________________
236et215.doc	Microsoft Word® Document	MS Word®	2002	42KB	1 page
Contents: Evidence Table 215. Study results: Cyclandelate
________________________________________________________________________________________________
237et216.doc	Microsoft Word® Document	MS Word®	2002	35KB	1 page
Contents: Evidence Table 216. Study results: Cyclandelate
________________________________________________________________________________________________
238et217.doc	Microsoft Word® Document	MS Word®	2002	40KB	1 page
Contents: Evidence Table 217. Study results: Desamino-D-Arginine-Vasapressin (DDAVP)
________________________________________________________________________________________________
239et218.doc	Microsoft Word® Document	MS Word®	2002	43KB	1 page
Contents: Evidence Table 218. Study results: Dihydroergokryptine (DEK)
________________________________________________________________________________________________
240et219.doc	Microsoft Word® Document	MS Word®	2002	37KB	1 page
Contents: Evidence Table 219. Study results: Denbufylline
________________________________________________________________________________________________
241et220.doc	Microsoft Word® Document	MS Word®	2002	33KB	1 page
Contents: Evidence Table 220. Study results: Desferrioxamine
________________________________________________________________________________________________
242et221.doc	Microsoft Word® Document	MS Word®	2002	37KB	1 page
Contents: Evidence Table 221. Study results: Diclofenac and Misoprostol (D/M)
________________________________________________________________________________________________
243et222.doc	Microsoft Word® Document	MS Word®	2002	40KB	1 page
Contents: Evidence Table 222. Study results: Glycoaminoglycan
________________________________________________________________________________________________
244et223.doc	Microsoft Word® Document	MS Word®	2002	47KB	2 pages
Contents: Evidence Table 223. Study results: Monosialotetrahexosylgan (GM-1)
________________________________________________________________________________________________
245et224.doc	Microsoft Word® Document	MS Word®	2002	37KB	1 page
Contents: Evidence Table 224. Study results: Guanfacine
________________________________________________________________________________________________
246et225.doc	Microsoft Word® Document	MS Word®	2002	36KB	1 page
Contents: Evidence Table 225. Study results: Hydergine-LC
________________________________________________________________________________________________
247et226.doc	Microsoft Word® Document	MS Word®	2002	36KB	1 page
Contents: Evidence Table 226. Study results: Hydroxychloroquine
________________________________________________________________________________________________
248et227.doc	Microsoft Word® Document	MS Word®	2002	35KB	1 page
Contents: Evidence Table 227. Study results: Indomethacin
________________________________________________________________________________________________
249et228.doc	Microsoft Word® Document	MS Word®	2002	35KB	1 page
Contents: Evidence Table 228. Study results: N-acetylcysteine (NAC)
________________________________________________________________________________________________
250et229.doc	Microsoft Word® Document	MS Word®	2002	37KB	1 page
Contents: Evidence Table 229. Study results: Nimesulide
________________________________________________________________________________________________
251et230.doc	Microsoft Word® Document	MS Word®	2002	38KB	1 page
Contents: Evidence Table 230. Study results: Nimodipine
________________________________________________________________________________________________
252et231.doc	Microsoft Word® Document	MS Word®	2002	37KB	1 page
Contents: Evidence Table 231. Study results: Nimodipine
________________________________________________________________________________________________
253et232.doc	Microsoft Word® Document	MS Word®	2002	35KB	1 page
Contents: Evidence Table 232. Study results: Nizatidine
________________________________________________________________________________________________
254et233.doc	Microsoft Word® Document	MS Word®	2002	34KB	1 page
Contents: Evidence Table 233. Study results: ACTH4-9 (Org 2766)
________________________________________________________________________________________________
255et234.doc	Microsoft Word® Document	MS Word®	2002	35KB	1 page
Contents: Evidence Table 234. Study results: ACTH 4-9 (Org 2766)
________________________________________________________________________________________________
256et235.doc	Microsoft Word® Document	MS Word®	2002	35KB	1 page
Contents: Evidence Table 235. Study results: Prednisone
________________________________________________________________________________________________
257et236.doc	Microsoft Word® Document	MS Word®	2002	36KB	1 page
Contents: Evidence Table 236. Study results: Simvastatin
________________________________________________________________________________________________
258et237.doc	Microsoft Word® Document	MS Word®	2002	34KB	1 page
Contents: Evidence Table 237. Study results: Thiamine
________________________________________________________________________________________________
259et238.doc	Microsoft Word® Document	MS Word®	2002	41KB	1 page
Contents: Evidence Table 238. Study results: Vincamine
________________________________________________________________________________________________
260et239.doc	Microsoft Word® Document	MS Word®	2002	37KB	1 page
Contents: Evidence Table 239. Study results: Piracetam
________________________________________________________________________________________________
261et240.doc	Microsoft Word® Document	MS Word®	2002	39KB	2 pages
Contents: Evidence Table 240. Study results: Xantinolnicotinate
________________________________________________________________________________________________
262et241.doc	Microsoft Word® Document	MS Word®	2002	38KB	1 page
Contents: Evidence Table 241. Study results: Donepezil (DPZ) - Vitamin E
________________________________________________________________________________________________
263et242.doc	Microsoft Word® Document	MS Word®	2002	34KB	1 page
Contents: Evidence Table 242. Study results: Fluoxetine
________________________________________________________________________________________________
264et243.doc	Microsoft Word® Document	MS Word®	2002	36KB	1 page
Contents: Evidence Table 243. Study results: 5'-MTHF - Trazodone
________________________________________________________________________________________________
265et244.doc	Microsoft Word® Document	MS Word®	2002	48KB	2 pages
Contents: Evidence Table 244. Study results: Citicoline
________________________________________________________________________________________________
266et245.doc	Microsoft Word® Document	MS Word®	2002	36KB	1 page
Contents: Evidence Table 245. Study results: Pyritinol - Hydergine
________________________________________________________________________________________________
267et246.doc	Microsoft Word® Document	MS Word®	2002	38KB	1 page
Contents: Evidence Table 246. Study results: Sulfomucopolysaccharides - Cytidine 
Diphosphocholine
________________________________________________________________________________________________
268et247.doc	Microsoft Word® Document	MS Word®	2002	35KB	1 page
Contents: Evidence Table 247. Study results: Sulodexide - Pentoxifylline
________________________________________________________________________________________________
269et248.doc	Microsoft Word® Document	MS Word®	2002	36KB	1 page
Contents: Evidence Table 248. Study results: Selegiline - Vitamin E
________________________________________________________________________________________________
270et249.doc	Microsoft Word® Document	MS Word®	2002	414KB	6 pages
Contents: Evidence Table 249. Adverse Events: Other agents
________________________________________________________________________________________________
271apdcv.doc	Microsoft Word® Document	MS Word®	2002	21KB	1 page
Contents: Cover Page: Appendix D. Peer review
________________________________________________________________________________________________
272apd1.doc	Microsoft Word® Document	MS Word®	2002	26KB	1 page
Contents: Peer Reviewers for the Treatment of Dementia Report
________________________________________________________________________________________________
273apd2.doc	Microsoft Word® Document	MS Word®	2002	29KB	2 pages
Contents: Structured format for collecting referee comments
________________________________________________________________________________________________
274apecv.doc	Microsoft Word® Document	MS Word®	2002	20KB	1 page
Contents: Cover Page: Appendix E. Outcome measures
________________________________________________________________________________________________
275appe.doc	Microsoft Word® Document	MS Word®	2002	203KB	9 pages
Contents: Appendix E. Outcome Measures
________________________________________________________________________________________________
276apfcv.doc	Microsoft Word® Document	MS Word®	2002	21KB	1 page
Contents: Cover Page: Appendix F. List of excluded studies
________________________________________________________________________________________________
277appf.doc	Microsoft Word® Document	MS Word®	2002	561KB	90 pages
Contents: Appendix F. List of excluded studies
________________________________________________________________________________________________

AHRQ Publication No. 04-E018-2
Current as of April 2004


Internet Citation:

Pharmacological Treatment of Dementia. File Inventory, Evidence Report/Technology Assessment Number 97. AHRQ Publication No. 04-E018-2, April 2004. Agency for Healthcare Research and Quality, Rockville, MD. http://www.ahrq.gov/clinic/demphinv.htm


Return to Evidence-based Practice
Clinical Information
AHRQ Home Page
Department of Health and Human Services